There are currently large efforts to make malaria prevention and treatment affordable, but unfortunately this is not quite sufficient, as my research with Doug Gollin shows. A larger problem is that prevention is not efficient enough, so that even at minimal costs you still have substantial malarial prevalence and large impacts on economies. Cost reductions like the one Keasling is generating will have an impact on the economic consequences of the disease, but unfortunately not its spread. It may in fact increase it, as people will find it less useful to protect themselves.
Against Monopoly
defending the right to innovate
Monopoly corrupts. Absolute monopoly corrupts absolutely.
Copyright Notice: We don't think much of copyright, so you can do what you want with the content on this blog. Of course we are hungry for publicity, so we would be pleased if you avoided plagiarism and gave us credit for what we have written. We encourage you not to impose copyright restrictions on your "derivative" works, but we won't try to stop you. For the legally or statist minded, you can consider yourself subject to a Creative Commons Attribution License.
Making malaria drugs available at low cost
As reported by Newsweek, a much more efficient way to produce artemisinin, which has a 90% cure rate for malaria, has been found by Berkeley chemical engineer Jay Keasling. Interestingly, he has no intention to get rich from it and has also made sure no one else will. The new drug will be marketed in 2010 at cost. Note, though, that he still patented his discovery. A better commitment would have been to let anyone use it.
[Posted at 02/27/2009 05:47 AM by Christian Zimmermann on Pharmaceutical Patents 
comments(0)]
Comments
Submit Comment
Most Recent Comments
How to extract money for using copyrighted performances The New York Times Magazine followed up on its earlier piece about The Copyright Enforcers with
at 08/29/2010 04:58 PM by John Bennett
NYTimes finds more IP news but doesn't report its consumer cost Enabling people to set up contests or awards of prizes is what I hope my Contingency Market can
at 08/28/2010 10:45 AM by Crosbie Fitch
NYTimes finds more IP news but doesn't report its consumer cost A couple of things can be done to encourage phamaceutical development without creating a monopoly.
at 08/28/2010 08:51 AM by John Bennett
Comment Posting Announcement Justin Levine's post has comments disabled again: Paul Allen Files Patent Lawsuits Against The
at 08/28/2010 03:18 AM by Crosbie Fitch
Germany Not many comments on that article. I presume that means it has a tiny audience.
Oh well, I guess
at 08/27/2010 03:22 PM by Crosbie Fitch
NYTimes finds more IP news but doesn't report its consumer cost To start with, shift the cost burden of later-stage clinical trials to the FDA and
at 08/27/2010 10:23 AM by Nobody Nowhere
NYTimes finds more IP news but doesn't report its consumer cost If I may ask a very simple question.
What would you do to encourage the "invention" of new and
at 08/27/2010 09:15 AM by MLS
Free textbooks If you are unable to get free textbooks but need cheap college books, I recommend visiting
at 08/27/2010 07:44 AM by Jay Taylor
Comment Posting Announcement Lewis Hyde's
Justin Levine has disabled
at 08/23/2010 03:25 PM by Anonymous
Music without copyright Thanks for the healthy info.
rent
at 08/23/2010 12:53 PM by Sue